MERCK KGAA

The global single-use bioreactors market is projected to reach USD 9.1 billion by 2029 from USD 4.4 billion in 2024, at a CAGR of 15.4%. The pharmaceutical & biotechnology companies segment dominated the market in 2023, driven by rising R&D initiatives and increased production of biologics and biosimilars. The US continues to lead the market, supported by active participation in biologics and biosimilars development and the advantages of single-use bioreactors.

Recursion and Exscientia complete AI-based drug development merger, creating a trans-Atlantic powerhouse with over 30 clinical and preclinical programs. The combined company, headquartered in Salt Lake City, focuses on oncology and rare diseases, with REC-617 (CDK7 inhibitor) and REC-994 (CCM treatment) as key candidates. The merger aims to generate $100 million in annual savings through operational synergies, including job cuts, and expects to receive over $20 billion in additional milestone payments from partnerships with Roche, Sanofi, Bayer, and others.

The Life Science Tools Market, valued at USD 158.40 billion in 2023, is projected to reach USD 407.57 billion by 2032, growing at a CAGR of 11.09%. Driven by precision medicine, genomics, and drug discovery, the market is bolstered by advancements in NGS, mass spectrometry, and AI-powered systems. Key players include Agilent Technologies, Thermo Fisher Scientific, and Illumina. North America leads the market, while Asia-Pacific shows the highest growth.

The global Nucleic Acid Isolation and Purification market is projected to grow from $7.6B in 2023 to $12B by 2030, driven by molecular diagnostics, genomics research, and personalized medicine. Technological advancements like automated systems and magnetic bead-based purification are key factors shaping the market.

Biotechnology Reagents & Kits Market to reach USD 1442.11 billion by 2032 at a CAGR of 10.97%, driven by R&D investments, synthetic biology, and genomic sequencing advancements.

CRISPR technology market to grow at 19.2% CAGR (2024-2031), driven by biomedical applications and increased R&D funding. Key players include Merck KGaA, Thermo Fisher Scientific, and Beam Therapeutics, focusing on genetic disorder treatments like sickle cell disease and Alpha-1 Antitrypsin Deficiency.

The global digital PCR market, valued at $678.1 million in 2023, is projected to reach $3.35 billion by 2034, driven by personalized medicine and technological advancements. Key players include Bio-Rad Laboratories, Thermo Fisher Scientific, and QIAGEN, with innovations like droplet digital PCR and microfluidic platforms. The market is segmented by product, application, and region, with North America leading growth and Asia-Pacific expected to grow significantly.

Merck KGaA and Abbisko Therapeutics report positive phase 3 MANEUVER trial results for pimicotinib in tenosynovial giant cell tumours (TGCTs), achieving a 54% objective response rate at week 25. The drug showed significant improvements in secondary endpoints and was well tolerated, with a safety profile consistent with previous data. Pimicotinib, an orally administered CSF-1R inhibitor, has been granted breakthrough therapy designation in the US and China, and priority medicine designation in the EU. Merck holds an exclusive licence to commercialise pimicotinib in China and has an option for the rest of the world.

The global Microarray Market is evolving due to tech advancements and sustainability emphasis. The report covers market trends, growth factors, and segmentation by product, type, and end-user. Key players include Thermo Fisher Scientific, Illumina, and Agilent Technologies. The market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The study forecasts market size, identifies drivers and restraints, and analyzes competitive developments.

The Biotechnology Reagents Market is projected to reach USD 1.07 billion by 2031, driven by rising R&D investments and technological advancements. Key players include Abbott, Agilent Technologies, Danaher, and Bio-Rad Laboratories. The market is expected to grow at a CAGR of 12.20% from 2022 to 2029, with North America leading in adoption.